Objective: To explore the possible role of Irisin in antipsychotic drug-induced insulin resistance and abdominal obesity in patients with schizophrenia and to provide a theoretical basis for the prevention of antipsychotic drug-induced obesity. Methods: Fifty-five patients with first-episode schizophrenia, from the First Affiliated Hospital of Zhengzhou University, between January 2016 and December 2017, were admitted as well as fifty healthy controls during the same period. Serum Irisin levels were measured by enzyme-linked immunosorbent assay (ELISA). Fasting blood glucose (FBG), fasting insulin (INS), homeostasis model assessment of insulin resistance (HOMA-IR) and triglyceride (TG), total cholesterol (TCHO), highdensity lipoprotein (HDL), low density lipoprotein (LDL) were detected. Results: The average Irisin level ((233±228) mmol/L) was higher than that in the normal control group ((124±89) mmol/L) (P<0.05).Repeated measurement analysis of variance showed that the average levels of the height, waist, FBG, INS, TCHO, TG, HDL, LDL, BMI, HOMA-IR and Irisin at the end of the 12(th) and 24(th) week's treatment were higher than baseline (P<0.05). After correlation analysis, the level of Irisinat baseline was positively correlated with HOMA-IR (r=0.383, P<0.05). At the 12(th) week, the level of Irisin was positively correlated with waist circumference, and HOMA-IR (r=0.360, r=0.475, all P<0.05). Multiple linear regression analysis showed that at the 12(th) week's treatment, compared with the baseline period, changes of Irisin was positively correlated with waist circumference and HOMA-IR, respectively (β=0.453, β=0.420, both P<0.05). Conclusion: Irisin may be involved in the process of metabolic regulation and bean early predictor of antipsychotic drug-induced insulin resistance and abdominal obesity.
目的： 探讨Irisin在抗精神病药源性胰岛素抵抗、腹型肥胖中的可能作用，为预防抗精神病药源性肥胖提供理论依据。 方法： 2016年1月至2017年12月郑州大学第一附属医院首发精神分裂症患者55例、健康对照50名。酶联免疫吸附试验（ELISA）测定血清Irisin水平；检测空腹血糖（FBG）、空腹胰岛素（INS）、胰岛素抵抗指数（HOMA-IR），以及三酰甘油（TG）、总胆固醇（TCHO）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）等指标。 结果： （1）病例组治疗前Irisin平均水平[（233±228）mmol/L]高于健康对照组[（124±89）mmol/L]（P<0.05）；（2）重复测量方差分析示：治疗12周末、24周末体质量、腰围、FBG、INS、TCHO、TG、HDL、LDL、BMI、HOMAIR以及Irisin水平均增加（P<0.05）；（3）相关分析示：病例组基线期Irisin与HOMA-IR正相关（r=0.383，P<0.05），治疗12周末Irisin与腰围、HOMA-IR正相关（r=0.360，r=0.475，均P<0.05）；多元线性回归分析示：治疗12周末，Irisin的变化与腰围、HOMA-IR的变化均正相关（β=0.453，β=0.420，均P<0.05）。 结论： Irisin可能参与了精神分裂症患者代谢调节过程，是抗精神病药源性胰岛素抵抗、腹型肥胖早期预测指标。.
Keywords: Insulinresistance; Irisin; Obesity; Schizophrenia.